Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS) or Uncoated Bare Metal Stent (EXPRESS2)

Trial Profile

Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS) or Uncoated Bare Metal Stent (EXPRESS2)

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Bivalirudin (Primary) ; Abciximab; Eptifibatide; Heparin; Paclitaxel; Tirofiban
  • Indications Myocardial infarction
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms HORIZONS-AMI; HORIZONS-AMI CMRI
  • Most Recent Events

    • 29 Mar 2017 Results of comparison of outcomes and prognostic factor in patients with versus without newly diagnosed daibetes mellitus published in the American Journal of Cardiology
    • 20 Apr 2016 Results of a pooled analysis from REPLACE-2, ACUITY and HORIZONS-AMI Trials (n=3641) published in the American Journal of Cardiology
    • 01 Dec 2015 Results(n=14,784) of pooled analysis of this and other two trials (see profile 4808 and 266431) published in the American Journal of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top